EvaluatePharma 2018 Outlook: Novartis #1 and Pfizer Sole USA Co in Top 5
LONDON, April 26, 2012 /CNW/ - EvaluatePharma Ltd, a leading source for life science sector analysis and the first to supply reliable consensus forecasts of global drug sales, revealed today that Novartis is expected to take the top spot amongst the world's pharmaceuticals manufacturers, in terms of prescription (Rx) drug sales, starting in 2014 and remains at the top through 2018. Only one US-based drug maker, Pfizer, will rank among the top five, with Sanofi, GlaxoSmithKline and Roche also topping the table. Further down the league table sizeable shifts both up and down the rankings are forecast, as pipeline successes and failures drive the future fortunes of the world's biggest pharma companies (see table).
For more in-depth analysis and commentary on this news please visit EP Vantage: http://ow.ly/awKnz.
| World's Top 15 Pharma Companies | |||||||||||||
| Market Rank | Rx Pharma Sales ($bn) | ||||||||||||
| Annual growth |
|||||||||||||
| 2011 | 2014 | 2016 | 2018 | 2011 | 2014 | 2016 | 2018 | 2011-18 | |||||
| Novartis | 2 | 1 | 1 | 1 | 46.7 | 47.6 | 49.0 | 50.8 | 1.2% | ||||
| Sanofi | 4 | 3 | 3 | 2 | 39.3 | 42.9 | 45.6 | 47.8 | 2.9% | ||||
| Pfizer | 1 | 2 | 2 | 3 | 53.5 | 46.9 | 46.5 | 47.1 | -1.8% | ||||
| GlaxoSmithKline | 6 | 6 | 4 | 4 | 35.0 | 38.5 | 43.1 | 45.6 | 3.9% | ||||
| Roche | 5 | 5 | 5 | 5 | 37.0 | 40.7 | 42.7 | 45.0 | 2.8% | ||||
| Merck & Co | 3 | 4 | 6 | 6 | 41.9 | 40.9 | 42.6 | 41.0 | -0.3% | ||||
| Johnson & Johnson | 9 | 8 | 7 | 7 | 22.3 | 25.8 | 27.2 | 27.3 | 2.9% | ||||
| Teva | 11 | 10 | 10 | 8 | 17.1 | 22.1 | 22.8 | 23.3 | 4.5% | ||||
| AstraZeneca | 7 | 7 | 8 | 9 | 32.4 | 26.7 | 25.2 | 22.1 | -5.3% | ||||
| Abbott Laboratories | 8 | 9 | 9 | 10 | 22.4 | 23.7 | 23.9 | 22.1 | -0.2% | ||||
| Bristol-Myers Squibb | 12 | 15 | 11 | 11 | 16.9 | 14.9 | 18.9 | 21.4 | 3.4% | ||||
| Novo Nordisk | 17 | 14 | 13 | 12 | 12.4 | 15.6 | 18.0 | 19.9 | 7.0% | ||||
| Takeda | 14 | 12 | 12 | 13 | 15.2 | 16.8 | 18.7 | 19.5 | 3.6% | ||||
| Bayer | 16 | 16 | 16 | 14 | 13.6 | 14.6 | 15.7 | 16.5 | 2.7% | ||||
| Gilead Sciences | 21 | 20 | 17 | 15 | 8.1 | 10.8 | 15.0 | 15.7 | 9.9% | ||||
About EvaluatePharma Ltd.
The market intelligence and analysis company EvaluatePharma Ltd was the first to supply reliable consensus forecasts of global drug sales and has just updated the standardized worldwide financial and forecast models with consensus product sales forecasts to 2018. EvaluatePharma also provides data on R&D pipelines, clinical trials, licensing deals, patent risk, M&A activity, valuation through product Net Present Value analysis plus daily commentary and analysis from the EP Vantage® news service.
EvaluatePharma Ltd, headquartered in London, England and in North America is represented by EvaluatePharma USA, Inc.
Media Contacts:
Andrew Beaven
Marketing Director, EvaluatePharma Ltd
Tel: +44(0)20-7377-0800
Email: [email protected]
EvaluatePharma Ltd
11-29 Fashion Street
London
E1 6PX
United Kingdom
Christine Lindgren
Tel: +1-617-573-9458
Email: [email protected]
EvaluatePharma USA
15 Broad St.
Boston, MA 02109
United States
Share this article